Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash & Equivalents (2016 - 2025)

Outlook Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $8.7 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 52.17% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 52.17% year-over-year, with the annual reading at $8.1 million for FY2025, 45.85% down from the prior year.
  • Cash & Equivalents was $8.7 million for Q4 2025 at Outlook Therapeutics, up from $8.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $14.9 million in Q3 2024 and troughed at $5.7 million in Q4 2024.